The landmark trials DCCT/EDIC trials show how important good glycaemic control is for the prevention of late complications in type 1 diabetes (T1D). According to the American Diabetes Association (ADA) an HbA1c target value of less than 7% should be targeted throughout all age groups to reduce the risk of late complications unless safety issues for individual patients or patients groups indicate higher HbA1c goals. However, most patients have difficulties to reach this target value despite improvements in diabetes therapy options during the last years. Especially the age group between 15 and 25 years have significantly higher HbA1c levels as analysis of data of various countries show . The analysis of an US database, the so-called T1D Exchange registry which contains data of more than 35000 patients with T1D, indicate that glycaemic control in adolescents and young adults seems to get even worse in the past years as from 2012 until 2018 the average HbA1c has increased, particularly in the younger age groups .